Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach

Clin Biochem. 2011 Apr;44(5-6):377-85. doi: 10.1016/j.clinbiochem.2011.01.002. Epub 2011 Jan 9.

Abstract

Objectives: Parkinson's disease (PD) ranks the second among the neurodegenerative disorders. Proteins involved in Parkinson's disease (PD) have been investigated but none as the diagnostic markers in blood.

Design and methods: In this study, we applied a proteomic strategy, by utilizing two-dimensional electrophoresis and mass spectrometry, to analyze two sample pools of plasma from the healthy individuals and PD subjects.

Results: IgGκL and human serum amyloid P component (SAP) were found differentially expressed between these pools. SAP level increased by approximately 5-fold in PD samples, and the ELISA procedure revealed a significant (P<0.001) increase in SAP concentration (65.9 ± 18.7μg/mL) in the plasma of PD subjects (healthy individuals, 35.0 ± 12.5μg/mL), with sensitivity of 94.1% and specificity of 87.5%.

Conclusion: Our results indicated a potential feasibility of plasma SAP as a marker to approach PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood*
  • Case-Control Studies
  • Electrophoresis, Gel, Two-Dimensional
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Mass Spectrometry
  • Middle Aged
  • Parkinson Disease / blood
  • Parkinson Disease / diagnosis*
  • Proteomics*
  • Serum Amyloid P-Component / metabolism*

Substances

  • Biomarkers
  • Serum Amyloid P-Component